Arcadia Biosciences (RKDA)
(Delayed Data from NSDQ)
$1.90 USD
-0.16 (-7.76%)
Updated Apr 25, 2024 03:54 PM ET
4-Sell of 5 4
D Value C Growth F Momentum D VGM
Balance Sheet
Fiscal Year End for Arcadia Biosciences, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 12 | 21 | 29 | 26 | 25 |
Receivables | 1 | 1 | 1 | 1 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 2 | 3 | 4 | 4 | 2 |
Other Current Assets | 1 | 1 | 1 | 1 | 1 |
Total Current Assets | 15 | 25 | 35 | 32 | 28 |
Net Property & Equipment | 0 | 1 | 2 | 4 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 3 | 1 | 2 | 3 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 1 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 2 | 0 |
Total Assets | 20 | 29 | 44 | 47 | 33 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 3 | 4 | 4 | 5 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 1 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 4 | 4 | 5 | 6 | 6 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 2 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 3 | 3 | 5 | 5 | 17 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 7 | 8 | 13 | 19 | 24 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 285 | 279 | 258 | 240 | 215 |
Retained Earnings | -272 | -258 | -226 | -212 | -207 |
Other Equity | 0 | 0 | 0 | 1 | 1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 13 | 21 | 31 | 29 | 8 |
Total Liabilities & Shareholder's Equity | 20 | 29 | 44 | 47 | 33 |
Total Common Equity | 13 | 21 | 31 | 29 | 8 |
Shares Outstanding | 1.10 | 0.60 | 0.50 | 0.50 | 0.20 |
Book Value Per Share | 11.55 | 34.83 | 62.40 | 57.10 | 41.65 |
Fiscal Year End for Arcadia Biosciences, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 12 | 16 | 19 | 23 |
Receivables | NA | 1 | 0 | 1 | 1 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 2 | 3 | 3 | 3 |
Other Current Assets | NA | 1 | 1 | 1 | 1 |
Total Current Assets | NA | 15 | 20 | 23 | 27 |
Net Property & Equipment | NA | 0 | 0 | 1 | 1 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 3 | 2 | 1 | 1 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 20 | 23 | 27 | 30 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 2 | 3 | 3 | 3 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 0 | 0 | 0 | 0 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 4 | 4 | 4 | 4 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 4 | 4 | 9 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 7 | 8 | 9 | 14 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 285 | 284 | 284 | 284 |
Retained Earnings | NA | -272 | -269 | -266 | -267 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 13 | 15 | 18 | 17 |
Total Liabilities & Shareholder's Equity | NA | 20 | 23 | 27 | 30 |
Total Common Equity | 0 | 13 | 15 | 18 | 17 |
Shares Outstanding | 1.30 | 1.10 | 1.10 | 0.80 | 0.80 |
Book Value Per Share | 0.00 | 11.55 | 14.00 | 22.16 | 20.86 |